The architecture of circulating neoantigen-specific immune memory in LS is defined and public TCRs are highlighted as candidates for immune monitoring and immunoprevention.
Abstract
Lynch syndrome (LS), a common inherited genetic condition predisposing to cancer, provides a unique model to study immune surveillance at the earliest stages of tumorigenesis. A hallmark of LS carcinogenesis is the generation of highly immunogenic neoantigens, yet the transcriptomic states of the T cells that recognize them remain poorly understood. Here, we characterize neoantigen-specific T cells from LS carriers using functional assays, single-cell RNA/T cell receptor (TCR) sequencing, and repertoire integration with existing large datasets. Recurrent neoantigens elicit strong immune responses, with neoantigen-specific T cells mediating cytotoxicity against tumor organoids. Single-cell analysis reveals oligoclonal expansions spanning effector and memory states with enrichment for exhausted subsets among cancer survivors and retention of polyfunctional effectors in cancer-free carriers. Cross-cohort analysis identifies public TCR clonotypes in circulation that overlap with pre-cancer and tumor tissue repertoires. Together, these findings define the architecture of circulating neoantigen-specific immune memory in LS and highlight public TCRs as candidates for immune monitoring and immunoprevention.
Pancreatic cancer (PC) is largely refractory to immune checkpoint blockade (ICB), although homologous recombination-deficient (HRD) tumors may derive benefit. In the POLAR trial of maintenance pembrolizumab plus olaparib after platinum-based chemotherapy for metastatic PC, responses remained heterogeneous. To define de...
M. Hilmi, J. Schoenfeld, Wilson H. McKerrow et al.· bioRxiv· 0 citations
Effective immunotherapeutic strategies for high-grade serous ovarian cancer (HGSOC) remain limited despite evidence of tumor immunogenicity. Here, we report the longitudinal immune characterization of a patient with homologous recombination-deficient HGSOC treated with a personalized neoantigen-based dendritic cell...
Laurent Beziaud, P. Szturz, A. Sarivalasis et al.· Cancer Immunology and Immuno...· 0 citations
Personalized mRNA neoantigen vaccines represent an emerging form of precision cancer immunotherapy designed to generate de novo T-cell responses against patient-specific tumor mutations. Their therapeutic activity, however, depends not only on neoantigen selection and vaccine-induced immune priming but also on whether...
T. Demircan, Berna Yıldırım, Halil İbrahim Ünsal et al.· International Journal of Mol...· 0 citations
TFiT (tumor-reactive features in T cells), a transcriptional classifier that identifies tumor-reactive T cells and stratifies immunotherapy, but not chemotherapy, response across independent MM and AML cohorts, supporting its specificity for T cell-mediated tumor control.
N. Kehl, T. Wagner, Simon Steiger et al.· Cancer Cell· 1 citation
A comprehensive single-cell multiomic analysis of primary human T cells exposed to exosomes derived from 17 genomically diverse TNBC cell lines and 35 patient samples uncovered conserved and subtype-specific immunomodulatory programs induced by TNBC exosomes.
Sanam Rezaei Benam, S. Maleknia, Kent Williams et al.· Signal Transduction and Targ...· 0 citations
Endometrial cancer (EC) is characterized by significant molecular and immunological heterogeneity, which influences both disease progression and response to therapy. Although immune checkpoint blockade has improved the clinical management of selected EC subtypes, durable responses remain limited in many patients, parti...
Alessandro Poggi, V. Bruno, Anna Di Spirito et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.